1
|
Scala L, Chi D, Bochner B, Andikyan V, Gerst S, Sandhu J, Boland P, Sonoda Y, Alektiar K. OC-46 HIGH DOSE RATE (HDR) INTRAOPERATIVE BRACHYTHERAPY IN THE MANAGEMENT OF RECURRENT GYNECOLOGIC MALIGNANCIES. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72013-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
2
|
Milowsky MI, Regazzi AM, Garcia-Grossman IR, Trout A, Flaherty A, Gerst S, Al-Ahmadie H, Ostrovnaya I, Bajorin DF. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4606] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Milowsky MI, Regazzi AM, Garcia-Grossman IR, Trout A, Flaherty A, Gerst S, Bajorin DF. Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.245] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
245 Background: Second-line chemotherapy has limited activity in advanced TCC with a median progression free survival (PFS) of 2-3 months. We have previously demonstrated the overexpression of activated mTOR pathway markers in invasive TCC specimens (BJU Int. 2010 Jul 26). Everolimus selectively inhibits mTOR, a central regulator of cell growth, proliferation, survival, and angiogenesis. This trial was designed to assess the efficacy of everolimus in patients (pts) with advanced TCC. Methods: The primary objectives of this single-institution phase II trial of everolimus in pts with TCC who have failed prior chemotherapy are 1) to measure PFS as determined by RECIST and 2) to evaluate toxicity. Prior therapy is restricted to ≤ 4 chemotherapy drugs. Pts receive everolimus 10 mg oral daily continuously (1 cycle = 4 weeks). A Simon 2-stage design requires ≥13 of 23 pts to be progression free at 2 months to proceed to maximal accrual of 37. Results: 43 pts (31 M, 12 F) with a median age of 65 yrs (32-84) and median KPS of 90 (70-90) were enrolled between 02/16/2009 and 09/30/2010. Primary tumor sites include bladder (32 pts) and ureter/renal pelvis (11 pts). Prior therapy included 28 pts with 2 drugs, 13 with 3 and 2 with 4. 34 pts have visceral metastases including lung (21), liver (19), and bone (5), and 9 pts have lymph node only disease. 8 pts who received ≤ 1 cycle secondary to rapid progression or toxicity unrelated to everolimus were deemed inevaluable for PFS endpoint and were replaced. To date, 33 pts are evaluable for the primary PFS endpoint; 2 pts are too early for PFS assessment. 22 of 33 pts are progression-free at 2 months. The median PFS for 33 evaluable pts is 2.9 months (1.4-9). One partial response has been seen. The most common grade 3-4 toxicities at least possibly related to everolimus include: anemia (7), infection (6), hyperglycemia (5), lymphopenia (4), hypophosphatemia (4), fatigue (3), hyponatremia (3), mucositis (2), dehydration (2), renal (2) and liver (2). Conclusions: Everolimus has clinical activity in pts with advanced TCC. An ongoing analysis of pretreatment tumor tissue specimens for markers of activated mTOR pathway will be correlated with PFS. [Table: see text]
Collapse
Affiliation(s)
| | - A. M. Regazzi
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - A. Trout
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. Flaherty
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Gerst
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. F. Bajorin
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
4
|
Krappmann K, Weikard R, Gerst S, Wolf C, Kühn C. A genetic predisposition for bovine neonatal pancytopenia is not due to mutations in coagulation factor XI. Vet J 2010; 190:225-229. [PMID: 21087874 DOI: 10.1016/j.tvjl.2010.10.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2010] [Revised: 10/07/2010] [Accepted: 10/17/2010] [Indexed: 11/29/2022]
Abstract
Bovine neonatal pancytopenia (BNP) is a newly emerging disease in many European countries that causes haemorrhagic diathesis and mortality in neonatal calves. This study tested the hypothesis that genetic factors might be involved in BNP, since genetic defects resulting in coagulation disorders have been described in many species, including cattle. A familial pattern of occurrence of BNP cases was observed in an experimental population of cattle in Germany and BNP was diagnosed in nine calves on an experimental dairy herd from May 2007 to December 2009. All affected calves were descendents of a single F(1) sire in a specific F(2) resource population generated from Charolais and German Holstein bloodlines. Sequence analysis of the bovine coagulation factor XI (F11) gene as a functional candidate gene for BNP revealed an unusually high number of non-synonymous mutations within the gene compared to a whole genome mutation screen in cattle targetting random sequences. However, none of the mutations in the F11 gene were concordant with BNP status. Although these data and further pedigree analysis excluded a simple mode of inheritance of the BNP phenotype, there was a statistically significant (P=0.0001) accumulation of BNP cases in the specific pedigree examined, suggesting that a genetic component is involved in the development of BNP.
Collapse
Affiliation(s)
- K Krappmann
- Research Unit Molecular Biology, Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany
| | - R Weikard
- Research Unit Molecular Biology, Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany
| | - S Gerst
- State Office for Agriculture, Food Safety and Fishery Mecklenburg-Western Pommerania (LALLF M-V), Thierfelderstraße 18, 18059 Rostock, Germany
| | - C Wolf
- State Office for Agriculture, Food Safety and Fishery Mecklenburg-Western Pommerania (LALLF M-V), Thierfelderstraße 18, 18059 Rostock, Germany
| | - Ch Kühn
- Research Unit Molecular Biology, Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, 18196 Dummerstorf, Germany.
| |
Collapse
|
5
|
Klopfleisch R, Wolf PU, Uhl W, Gerst S, Harder T, Starick E, Vahlenkamp TW, Mettenleiter TC, Teifke JP. Distribution of lesions and antigen of highly pathogenic avian influenza virus A/Swan/Germany/R65/06 (H5N1) in domestic cats after presumptive infection by wild birds. Vet Pathol 2007; 44:261-8. [PMID: 17491066 DOI: 10.1354/vp.44-3-261] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In early 2006, the highly pathogenic avian influenza virus (HPAIV) H5N1 of the Asian lineage caused the death of wild aquatic birds in Northern Germany. In the mainly affected areas, a trans-species transmission of HPAIV H5N1 to mammals occurred between birds and domestic cats and 1 Stone Marten (Martes foina), respectively. Here, we report lesions and distribution of influenza virus antigen in 3 cats infected naturally with HPAIV H5N1 A/swan/Germany/R65/06. The hemagglutinin partial nucleotide sequences of the viruses were genetically closely related to a H5N1 HPAIV obtained from a dead Whooper Swan (Cygnus cygnus) of the same area. At necropsy, within the patchy dark-red and consolidated lungs, there was granulomatous pneumonia caused by Aelurostrongylus sp. Histologically, the main findings associated with influenza in all cats were bronchointerstitial pneumonia and marked random hepatic necrosis. In addition, all animals displayed lymphoid necrosis in the spleen and Peyer's patches and necrosis of the adrenal cortex. Immunohistochemically, nucleoprotein of HPAIV was present intralesionally in the lungs, liver, adrenal glands, and lymphoid tissues. Oropharyngeal swabs were shown to be suited to detect HPAIV by quantitative real-time polymerase chain reaction (RT-PCR) in these cats, despite the paucity of influenza virus antigen in the upper respiratory tract by means of immunohistochemistry. The results show that outdoor cats in areas affected by HPAIV in wild birds are at risk for lethal infection. In conclusion, hepatic necrosis was, besides bronchointerstitial pneumonia, the primary lesion, suggesting that in naturally infected cats, damage to the liver plays an important role in the pathogenesis of H5N1 influenza.
Collapse
Affiliation(s)
- R Klopfleisch
- Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Isle of Riems, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Bell-McGuinn KM, Konner J, Pandit-Taskar N, Gerst S, Nicolaides N, Sass P, Grasso L, Weil S, Phillips M, Aghajanian C. A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5553 Background: Folate receptor alpha (FRA) is over-expressed in the majority of epithelial ovarian cancers (EOC) but is largely absent from normal tissue. MORAb-003 is a humanized monoclonal antibody (MAb) to FRA. Binding of MORAb-003 to FRA can prevent phosphorylation of substrates specific for Lyn kinase, suppress proliferation of cells over-expressing FRA, mediate FRA-positive tumor cell killing via antibody-dependent cellular and complement-dependent mechanisms, and suppress tumor growth in vivo of FRA-expressing tumors in rodent xenograft models. Toxicology studies in non-human primates found no evidence of toxicity with MORAb-003 at supra- pharmacological doses. This open-label, multiple-infusion, first-in-human, dose-escalation trial evaluates the safety, pharmacokinetics (PK), and anti-tumor activity of MORAb-003 in patients with platinum-resistant EOC. Methods: Sequential cohorts of patients received four weekly infusions at escalating dose levels of MORAb-003 from 12.5 mg/m2 to 400 mg/m2. Eligible patients had platinum-resistant EOC, acceptable organ function, KPS = 70%, and measurable disease by GOG-RECIST criteria. A subset of subjects received a tracer dose of 111In-labelled MORAb-003 and SPECT-CT and planar imaging. Human anti-human antibody (HAHA) and PK analyses were performed. Results: To date, 18 subjects have been dosed with up to 200 mg/m2. No dose limiting toxicity or significant related adverse events have been observed. Four subjects had rigors (2 grade 1) or fevers (3 grade 1, 1 grade 2) following the first infusion. Nine subjects have had radiologically stable disease, and 7 subjects have had stable or declining CA125. Two subjects have received extended therapy for an apparent clinical benefit. Radiolabelled tracer studies have demonstrated significant tumor uptake of labeled MORAb-003. The 400 mg/m2 dose cohort is currently enrolling. Conclusions: The FRA-specific MAb MORAb-003 appears to be well tolerated in patients with EOC and may have activity in platinum-resistant patients. These results support further evaluation of the efficacy of MORAb-003 in a phase 2 study which is ongoing. [Table: see text]
Collapse
Affiliation(s)
- K. M. Bell-McGuinn
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - J. Konner
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - N. Pandit-Taskar
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - S. Gerst
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - N. Nicolaides
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - P. Sass
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - L. Grasso
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - S. Weil
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - M. Phillips
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| | - C. Aghajanian
- Memorial Sloan Kettering Cancer Center, New York, NY; Morphotek Inc., Exton, PA
| |
Collapse
|
7
|
Rietschel P, Ejadi S, Wolchok J, Krown S, Gerst S, Jungbluth A, Busam K, Panageas K, Smith K, Chapman P. Phase II trial of extended-dosing temozolomide in patients with melanoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8531 Background: To test the hypothesis that the ∼30% response rate we observed in metastatic melanoma (mel) patients (pts) treated with temozolomide (TMZ) using an extended dosing schedule with either thalidomide or interferon was largely due to TMZ alone, we conducted a phase II trial of TMZ alone. We also hypothesized that mel expression of methylguanine methyltransferase (MGMT) would correlate with drug resistance. Methods: Stage IV mel pts without brain metastases or prior chemotherapy were stratified into two cohorts based on whether or not they had stage M1c disease. Each cycle consisted of TMZ 75 mg/m2/day for 6 weeks followed by 2 weeks with no treatment. Treatment cycles were repeated as long as pts did not progress. The primary endpoint was the proportion of complete or partial responses by RECIST criteria. The trial was powered to exclude the null hypothesis that the response rate in each cohort was <30%. MGMT promoter methylation status was assessed by methylation-specific pyrosequencing. In pts with insufficient tumor material for pyrosequencing, MGMT expression was measured by immunohistochemistry using the monoclonal antibody MT3.1. Results: To date we have accrued 48 pts, 23 in the M1c cohort. 7 pts are still receiving treatment and are not yet evaluable for response. There have been 4 partial responses observed, 2 in each cohort. The median number of cycles was 2 (range 1–6). 9/41 pts (22%) were stable for =6 months and received =3 cycles. 56% of pts developed CD4+ lymphopenia (<500/μl) during treatment; 37% of pts developed CD4+ lymphopenia <200/μl and received PCP prophylaxis. Opportunistic infections were not observed. Conclusions: The overall response rate is 9.8% (95% CI 0.8%-19%). The estimated median survival is 11 months for the stage III/M1a/b cohort and 9.7 months for the M1c cohort. To date, the response proportion to TMZ alone appears to be <30%. There would need to be 3 more responses in a cohort to reject the null hypothesis for that cohort. MGMT analyses are ongoing and will be used to determine if promoter methylation status correlates with objective response rate or time to progression. The study was supported by Schering-Plough. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Rietschel
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Ejadi
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Wolchok
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Krown
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Gerst
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - A. Jungbluth
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Busam
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Panageas
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Smith
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Chapman
- Maimonides Cancer Center, Brooklyn, NY; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
8
|
Sovak MA, Dupont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR, Aghajanian C. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007; 17:197-203. [PMID: 17291253 DOI: 10.1111/j.1525-1438.2006.00746.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The aim of this study was to assess the efficacy and tolerability of paclitaxel and carboplatin (TC) in the treatment of patients with advanced or recurrent endometrial cancer. Patients eligible for this retrospective analysis had endometrial cancer with either advanced or recurrent measurable disease (untreated primary stage III/IV or stage III/IV patients with persistent, measurable disease [≥2 cm] after surgery), Eastern Cooperative Oncology Group (ECOG) performance status ≥3, and received at least one cycle of TC. Response rates were determined using Response Evaluation Criteria in Solid Tumors criteria. Institutional Review Board approval was obtained prior to the initiation of this study. Eighty-five eligible patients, with a median age of 62 years (range 36–80) were identified. Fifty-seven (67%) of patients were treated at the time of recurrence. Prior radiation therapy had been used in the treatment of 36 (42%) patients, while 13 (15%) patients had received prior chemotherapy. Median follow-up time was 11.7 months (range 1.1–96.7 months), and the median number of cycles of therapy received was six (range 1–18). The overall response rate (ORR) was 43%, with a complete response rate of 5% and a partial response rate of 38%. Chemotherapy-naive patients had an ORR of 47%. Only seven (8%) patients had to discontinue therapy due to toxicity. Median progression-free survival was 5.3 months (95% CI, 4.6–7.4), with a median overall survival of 13.2 months (95% CI, 11.7–18.2). We conclude that TC is an active and tolerable regimen in the treatment of patients with advanced or recurrent endometrial cancer
Collapse
Affiliation(s)
- M A Sovak
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Rietschel P, Ejadi S, Wolchok J, Krown S, Gerst S, Jungbluth AA, Busam K, Smith K, Panageas K, Chapman P. Phase II trial of extended-dosing temozolomide in patients with melanoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8042 Background: We previously reported a 30% response rate in metastatic melanoma (mel) patients (pts) treated with temozolomide (TMZ) using an extended dosing schedule of 6 weeks on/ 2 weeks off with either thalidomide or interferon. We hypothesized that these responses were largely due to TMZ alone and conducted a phase II trial using extended dosing TMZ alone. We also tested the hypothesis that a) mel expression of methylguanine methyltransferase (MGMT) would correlate with drug resistance, and b) TMZ would cause decreased CD4+ T cell function during the first cycle of therapy. Methods: A phase II trial stratified metastatic mel patients into two cohorts based on whether or not they had stage IV M1c. 25 patients/cohort are planned. No brain metastases or prior chemotherapy were allowed. Each cycle consisted of TMZ 75mg/m2/day for 6 weeks followed by 2 weeks with no treatment. Primary endpoint was the proportion of objective responses by RECIST criteria. The trial was powered to exclude the null hypothesis that the response rate in each cohort was ≤10%. MGMT promoter methylation status was assessed by methylation-specific PCR. MGMT tumor expression was measured by immunohistochemistry (IHC). CD4+ T cell function was assessed by measuring interferon-γ responses to CMV by intracellular cytokine FACS analysis (FastImmune, BD Biosciences) at pretreatment, week 4 and week 8 of cycle 1. Results: To date 19 evaluable pts, 8 in the M1c cohort, have progressed with no objective responses; 6 other patients are currently on study. 4/19 pts who have gone off study because of progression were stable for 6 months and received ≥3 cycles. To date, 14/15 tumors analyzed for MGMT promoter methylation were unmethylated (≤15%). Promoter methylation of 21% was seen in one tumor. Conclusions: The MGMT promoter of metastatic mel tumors are hypomethylated predicting expression of the enzyme. This is being assessed directly by IHC and will be correlated with promoter methylation and clinical response. The effect of TMZ on anti-CMV CD4+ T cell function is being assessed. Accrual is ongoing and will be completed in Spring 2006. The study was supported by Schering-Plough. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Rietschel
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Ejadi
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Wolchok
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Krown
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Gerst
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | | - K. Busam
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Smith
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Panageas
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Chapman
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
10
|
Konner JA, Ahmed S, Gerst S, Vander Els N, Pezzuli S, Sabbatini P, Hensley M, Dupont J, Tew W, Aghajanian C. Phase I study of MORAb-003, a humanized anti-folate receptor-alpha monoclonal antibody, in platinum resistant ovarian cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5027 Background: Folate receptor alpha (FRA) is over-expressed in the majority of epithelial ovarian cancers (EOC) but largely absent from normal tissue. MORAb-003 (M3) is a humanized monoclonal antibody (MAb) to FRA. Binding of M3 to FRA can prevent phosphorylation of substrates specific for the Lyn kinase; suppress proliferation of cells over-expressing FRA; mediate FRA-positive tumor cell killing via antibody-dependent cellular and complement-dependent mechanisms; and suppress tumor growth in vivo of FRA-expressing tumors in rodent xenograft models. Toxicology studies in non-human primates found no evidence of toxicity with M3 at supra-pharmacological doses. This open-label, multiple-infusion, first-in-human, dose-escalation trial evaluates the safety, pharmacokinetics (PK), and antitumor activity of M3 in patients with platinum-resistant EOC. Methods: Sequential cohorts of patients receive four weekly infusions at escalating dose levels of M3, from 12.5 mg/m2 to 100 mg/m2. Human anti-human antibody (HAHA) and PK analyses are performed. Eligible patients have EOC that relapsed < 6 months after platinum-based therapy, acceptable organ function, Karnofsky Performance Status ≥ 70%, and measurable disease by GOG-RECIST criteria. Patients undergo pulmonary function testing (PFT) at baseline, and at end of study. Results: To date, 7 women have been treated with M3: 3 at the 12.5 mg/m2 dose, 3 at 25 mg/m2, and 1 at 37.5 mg/m2. Median age was 60. Neither dose limiting toxicity nor HAHA has been observed. Grade 1 rash occurred in 1 patient. Grade 1/2 fever following drug administration occurred in 2 patients. Grade 2 FEV1 decrease was observed in a patient with likely pulmonary lymphangitic metastasis. One subject at 25 mg/m2 had radiographically stable disease. At low doses, the PK analysis demonstrated the half-life to be shorter than anticipated based on animal studies, possibly due to tumor binding. Radiolableled imaging studies are underway to determine the distribution of M3. Conclusions: The FRA-specific MAb MORAb-003 appears to be well tolerated in patients with EOC. Enrollment continues and updated results will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Konner
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Ahmed
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Gerst
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. Vander Els
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Pezzuli
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - P. Sabbatini
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Hensley
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Dupont
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - W. Tew
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - C. Aghajanian
- Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
11
|
Aghajanian C, Sabbatini P, Derosa F, Gerst S, Spriggs DR, Dupont J, Hensley ML, Pezzulli S, Konner J, Schilder RJ. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5047] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Aghajanian
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - P. Sabbatini
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - F. Derosa
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - S. Gerst
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - D. R. Spriggs
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - J. Dupont
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - M. L. Hensley
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - S. Pezzulli
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - J. Konner
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| | - R. J. Schilder
- Memorial Sloan-Kettering Cancer Ctr, New York, NY; Fox Chase Cancer Ctr, Philadelphia, PA
| |
Collapse
|
12
|
Simon G, Sovak M, Wagner M, Haura E, Gerst S, deAlwis D, Bepler G, Sullivan D, Weitzman A, Spriggs D. 228 A phase I trial of LY573636 in patients with advanced solid tumors. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80236-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
13
|
Gerst S, Borchers K, Gower SM, Smith KC. Detection of EHV-1 and EHV-4 in placental sections of naturally occurring EHV-1- and EHV-4-related abortions in the UK: use of the placenta in diagnosis. Equine Vet J 2003; 35:430-3. [PMID: 12875318 DOI: 10.2746/042516403775600451] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
REASONS FOR PERFORMING STUDY EHV-1 and EHV-4 abortion diagnosis is based upon detailed examination of the aborted fetus. However, in some cases, only the placenta is available for examination. Furthermore, the contribution of lesions in the placenta to pathogenesis and diagnosis of EHV-1 and EHV-4 abortion has been neglected. OBJECTIVES To assess the utility of placental examination in equine herpesvirus-1 (EHV-1) and EHV-4 abortion diagnosis. METHODS Sections of allantochorion from 49 herpesvirus abortions were analysed by PCR, in situ hybridisation and immunostaining. RESULTS Virus-specific nested PCR confirmed the presence of viral DNA in 46 cases; 41 cases were EHV-1-positive and 5 EHV-4-positive. Microscopic changes were nonspecific. Examination of the PCR-positive sections of allantochorion revealed EHV-1 DNA by in situ hybridisation (ISH) in 21 cases and EHV-4 in 4 cases. In 2 samples, DNA of both viruses was present on PCR and ISH. Viral antigen was found by immunohistology in 15 cases. Regarding the localisation of virus in the placentae, both viral DNA and antigen of EHV-1 and EHV-4 were found in endothelial cells of chorionic villi and, occasionally, in trophoblast epithelium. In the stromal endothelium, only EHV-1 was found. CONCLUSIONS The data indicate that examination of placentae is a useful diagnostic aid in EHV-1 and EHV-4 abortion diagnosis. POTENTIAL RELEVANCE Virological examination of the placenta should become standard practice in equine abortion investigations, particularly in those cases where the fetus is not available for examination.
Collapse
Affiliation(s)
- S Gerst
- Institute of Virology, Free University of Berlin, Königin-Luise-Strasse 49, D-14195 Berlin, Germany
| | | | | | | |
Collapse
|